

The following investigators attended the Meeting: Guido Finazzi (Bergamo), Tiziano Barbui (Bergamo), Giovanni Barosi (Pavia), Heinz Gisslinger (Wien), Gunnar Birgegard (Uppsala), Annette Schmitt-Graff (Freiburg), Hans Hasselbalch (Denmark), J.J.Michiels (The Netherlands), Pinhas Stark (Israel), Christian Langer for Martin Griesshammer (Ulm), Andreas Reiter (Heidelberg), Francisco Cervantes (Barcelona), Holger Cario (Ulm)

Deliverables months 1-12

Guido Finazzi introduced the meeting and reviewed the list of deliverables due to 31.12.2004. Deliverables 9.1, 9.3, 9.4, 9.6 9.11 (and 9.15) are ready. Deliverable 9.2 is up to dr.Reiter who accepted to be the “web editor” of our WP. Deliverables 9.5 and 9.7 are due by dr.Barosi, 9.8 by drs. Lengfelder and Hasselbalch, 9.9 by drs. Gisslinger and Lengfelder, 9.10 by drs. Hasselbalch and Birgegard and 9.12 by dr. Rambaldi and Frassoni. This deliverables should be prepared and sent to me as soon as possible.

Plan for future studies (deliverables months 13-30)

The investigators agreed to plan the following clinical studies (deliverable 9.13): a) a common protocol for Imatinib therapy in PV patients. The protocol will be prepared by drs. Hasselbalch and Lengfelder; b) phase II studies of Velcade and Revlimid in MPDs: protocols up to dr. Barosi and Gisslinger respectively; c) a follow-up registration of patients treated with Anagrelide, to be prepared by dr Birgegard; d) a pilot clinical trial of two regimens of phlebotomy therapy in patients with PV, up to drs. Barbui, Finazzi and Marchioli. The proposed draft protocols will be discussed by the Investigators before starting the studies. Thus, ideally, the drafts should be ready for the next WP9 meeting to be held in Heidelberg February 1-3, 2005.

In addition, dr. Barosi accepted to prepare a questionnaire to be distributed among clinical investigators active in the field of CMPs asking for their feeling about “the most relevant open questions”. The answers will be the basis for planning future collaborative studies or guidelines preparations (deliverable 9.14).

Finally, proposals for Registries of rare conditions in MPDs are welcome, such as pediatric cases (dr. Cario), leukemic complications (dr. Gisslinger) or bcr-abl negative CML-like disorders (dr. Reiter).

We meet in Heidelberg February 1-3, 2005 at the 2nd Symposium of the LeukemiaNet.

Best wishes to all.

Guido Finazzi, for the Lead Participants (T. Barbui and G. Barosi), Bergamo
10/12/04